Patent intelligence · US
US 11096956
Antisense oligomers and uses thereof
Antisense oligomers and uses thereof
Patent details — US 11096956
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 24, 2021
- Expiration
- Aug 19, 2041
- Applicant
- STOKE THERAPEUTICS, INC.
- Claims
- 20
- CPC classes
- A61K, A61K31/7125, A61K38/005, A61K38/179
Quick answer
US 11096956 (Antisense oligomers and uses thereof) is held by STOKE THERAPEUTICS, INC.. Status: granted. Granted Aug 24, 2021. Expires Aug 19, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- STOKE THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/7125, A61K38/005, A61K38/179, A61K47/6807, A61P
More from STOKE THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12338437
OPA1 antisense oligomers for treatment of conditions and diseases
granted -
US 12060558
Methods and compositions for treatment of cholesteryl ester storage disease
granted -
US 11873490
Antisense oligomers for treatment of conditions and diseases
granted -
US 11814622
OPA1 antisense oligomers for treatment of conditions and diseases
granted -
US 11083745
Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome
granted -
US 10913947
Antisense oligomers for treatment of conditions and diseases
granted -
US 10683503
Antisense oligomers for treatment of conditions and diseases
granted
Frequently asked questions
What is US patent 11096956?
US 11096956 (Antisense oligomers and uses thereof) is held by STOKE THERAPEUTICS, INC.. Status: granted. Granted Aug 24, 2021. Expires Aug 19, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11096956?
STOKE THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 11096956 expire?
Our index shows an expiration date of Aug 19, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.